Skip to content
Peptigraph home

REDEFINE 3: CagriSema Phase 3 trial (NCT05669755)

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Registry record checked

At a glance

Phase
Phase 3
Status
Active, not recruiting
Enrolment
7,101
actual
Start
1 Mar 2023 (actual)
Primary completion
1 Sep 2027 (estimated)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT05669755 study arms
ArmTypeInterventionsDescription
CagriSemaExperimentalDrug: Cagrilintide; Drug: SemaglutideParticipants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks.
Endpoints

Primary endpoint

NCT05669755 primary outcomes
MeasureTime frame
Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal strokeFrom baseline (week 0) to end of study (up to 242 weeks or more)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05669755 secondary outcomes
MeasureTime frame
Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV deathFrom baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney deathFrom baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisationFrom baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal strokeFrom baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of myocardial infarction (fatal and non-fatal)From baseline (week 0) to end of study (up to 242 weeks or more)
Time to first occurrence of stroke (fatal and non-fatal)From baseline (week 0) to end of study (up to 242 weeks or more)
Change in eGFRcr (CKD-EPI)From baseline (week 0) to 120 weeks
Ratio to baseline in Urine albumin-to-creatinine ratio (UACR)From baseline (week 0) to 120 weeks
Relative change in body weightFrom baseline (week 0) to 120 weeks
Change in waist circumferenceFrom baseline (week 0) to 120 weeks
Change in waist-to-height ratioFrom baseline (week 0) to 120 weeks
Change in systolic blood pressure (SBP)From baseline (week 0) to 120 weeks
Eligibility

Who could enrol

Sex
All
Minimum age
55 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.